Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
Rhea-AI Summary
Daré Bioscience (NASDAQ: DARE) will host a conference call and live webcast at 4:30 p.m. ET on March 26, 2026 to review full year 2025 financial results and provide a company update.
Dial-in numbers are (646) 307-1963 or (800) 715-9871 with conference ID 1717423. The webcast is at http://ir.darebioscience.com and will be archived for replay until April 9, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – DARE
In the Mar 20 session, DARE gained 4.62%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Q3 2025 call notice | Neutral | -1.6% | Announced Q3 2025 earnings call and webcast with access details and replay dates. |
| Aug 07 | Q2 2025 call notice | Neutral | -9.7% | Scheduled Q2 2025 results call and webcast, providing dial-in numbers and archive info. |
| May 06 | Q1 2025 call notice | Neutral | -4.0% | Set date and time for Q1 2025 earnings call and investor webcast replay. |
| Mar 24 | FY 2024 call notice | Neutral | -0.5% | Announced full-year 2024 financial results call and company update webcast schedule. |
| Nov 07 | Q3 2024 call notice | Neutral | +2.8% | Planned Q3 2024 results call, with details on timing, access and replay period. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Similar conference/earnings call announcements for DARE have typically seen modest share price weakness, with an average move of about -2.61% and mostly negative next-day reactions.
Over the past five quarters, Daré Bioscience has regularly pre-announced conference calls to discuss results and provide company updates. Prior notices in November 2024, March 2025, May 2025, August 2025, and November 2025 all followed the same format, specifying call times, access numbers, and replay windows. These announcements often coincided with slight share price declines, suggesting investors tend to treat them as routine rather than as standalone catalysts.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 26, 2026, to review its financial results for the year ended December 31, 2025 and to provide a company update.
To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 1717423. The live webcast can be accessed under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install any necessary software. The webcast will be archived in the same section of the company's website and available for replay until April 9, 2026.
About Daré Bioscience
Daré Bioscience is a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions. Every innovation Daré advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, pelvic pain to fertility, vaginal health to infectious disease, Daré is working to close critical gaps in care using science that serves her needs.
For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to real, evidence-based solutions continues to lag. Daré was founded to change that. As a female-led health biotech company, Daré is accelerating the development of credible, science-based solutions that meet the high standards of clinical rigor – randomized, controlled trials; validated endpoints; peer-reviewed publications; and current Good Manufacturing Practice (cGMP) requirements.
To learn more about Daré’s mission to deliver differentiated therapies for women and its innovation pipeline, please visit www.darebioscience.com.
Daré Bioscience leadership has been named on the Medicine Maker’s Power List and Endpoints News’ Women in Biopharma and Daré's CEO has been honored as one of Fierce Pharma’s Most Influential People in Biopharma for Daré’s contributions to innovation and advocacy in the women’s health space.
Daré may announce material information about its finances, products and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, products and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.
Contacts:
Daré Bioscience Investor Relations
innovations@darebioscience.com
Source: Daré Bioscience, Inc.
